by Elec23 | Jul 1, 2026 | News&events, VisMederi
First identified in Uganda in 2007, Bundibugyo ebolavirus is one of the species of the Ebola virus. Although it has historically shown a lower case fatality rate than some other Ebola virus species, typically between 25% and 40%, it remains a serious public health...
by Elec23 | Jun 19, 2026 | News&events, VisMederi
From kit design and manufacturing to biological sample management and laboratory testing, VisMederi offers a fully integrated solution for clinical trials and research programs worldwide. VisMederi, a company specialized in vaccine evaluation through advanced...
by Elec23 | Jun 18, 2026 | News&events, VisMederi
VisMederi and CEVAC, a Belgian vaccine research center comprising a Clinical Trial Unit and an Immunomonitoring Laboratory, have signed a Memorandum of Understanding (MoU) to strengthen their collaboration in vaccine clinical trials, a core area of expertise for both...
by Elec23 | May 26, 2026 | News&events, VisMederi
VisMederi and KingMylab have announced the signing of a strategic collaboration agreement aimed at strengthening testing and analytical services for vaccine and biologics clinical trials. The partnership combines KingMylab’s expertise in central laboratory...
by Elec23 | Mar 11, 2026 | News&events, VisMederi
VisMederi highlighted its collaboration with Sumitomo Pharma Co., Ltd. and Japan’s National Institutes of Biomedical Innovation, Health and Nutrition (NIBN) in the European Phase 1 clinical programme evaluating a universal influenza vaccine candidate formulated with...
